

AMENDMENT

Kindly amend the application as follows.

In the Specification:

Please amend page 43, lines 8-10 to read as follows.

SEQ ID NO: 27 Lys-Leu-Val-Phe-Phe-Ala-Glu (all-D)

β¹ SEQ ID NO: 28 Lys-Leu-Val-Phe-Phe-Ala-Glu-NH₂ (all-D)

SEQ ID NO: 29 His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu (all-D)

Please amend page 44, lines 15-17 to read as follows.

The following are exemplary compounds derived from compound 20 (all-D

β² KLVFFA-NH₂; SEQ ID NO: 20) by substituting one or two amino acid residue(s) with other amino acids.

In the Claims:

Please cancel claims 9-11 and 18-20, and amend claims 1-4, 6-8, and 12-17 to read as follows.

- β³
1. (Amended) A method for preventing or treating an amyloid-related disease in a subject, comprising: administering to the subject an antigenic amount of an all-D peptide, wherein said all-D peptide elicits the production of antibodies against said all-D peptide and induces an immune response by said subject, thereby preventing or reducing amyloid-induced neurodegeneration or amyloid fibril formation.